| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Funder | Competition | Research | Implementation/Clinical Care | KX/ Travel | Education | Open to projects outside of Canada? | Lead must be based in Canada? | Key words | Due date | Max value | Currency | Length (months) | Website | |||||||||||||
2 | TDR | Generating evidence on the implementation and impact of digital solutions for infectious diseases of poverty in LMIC settings | Y | N | N | N | Y | N | Invites applications from LMIC-based institutions for projects to generate evidence on the adoption, integration, and impact of digital health tools addressing infectious diseases of poverty, focusing on real-world use, health system integration, and outcomes such as equity and acceptability, with a preference for tools supporting patients, community members, or frontline health workers. | October 15, 2026 | 50,000 | USD | 12 | https://who.my.site.com/etdr/s/gs-solicitation/a0pVj000007mGw5IAE/ca260034 | |||||||||||||
3 | CIFAR | Global Scholars Program | Y | N | Y | Y | Y | N | Offers early-career researchers the opportunity to develop and lead high-risk, high-reward interdisciplinary research, expand their professional networks and receive focused leadership training in their pivotal first years as independent principal investigators. Open to applicants holding a PhD (or equivalent) from any country. Funds are unrestricted and not tied to a specific project or proposal. | November 4, 2026 | 100,000 | CAD | 24 | https://cifar.ca/next-generation/global-scholars/ | |||||||||||||
4 | CEPI | Focus Area 2: Vaccine candidates for priority pathogens and viral families | Y | Y | N | N | Y | N | Objective for Focus Area 2 is to advance new vaccine candidates for CEPI priority pathogens and viral families, aligned with CEPI’s strategic objectives to accelerate development of vaccines against known high-risk pathogens and to build a library of exemplar vaccines against prototype viruses from high-risk viral families to give a head-start on novel threats (Disease X). | December 13, 2026 | 5,000,000 | USD | 18 - 60 | https://cepi.my.site.com/call-for-proposal?id=a1zP3000001Dz3VIAS | |||||||||||||
5 | CEPI | Innovations to Prepare for Future Epidemics and Pandemics | Y | N | N | N | Y | N | For (1) innovative vaccine platforms that can transform outbreak response to Disease X, addressing needs for speed, safety/efficacy, and access; or (2) advance new vaccine candidates for CEPI priority pathogens and viral families. | Rolling until December 2026 | 5,000,000 | USD | 36 - 60 | https://cepi.net/calls-for-proposals?selectedProposal=9bde4615-b7b1-5f00-a079-a3080e88a845&selectedProposal=c08cff7c-f002-506a-8afb-cc2e921056ae | |||||||||||||
6 | Health Research BC | Match Funding | Y | N | N | N | N | Y | Applying to peer-reviewed, non-BC-government-funded research competition that requires match funding; Link to human health; Must be used in BC | 5 weeks before competition deadline | https://healthresearchbc.ca/match-funding/ | ||||||||||||||||
7 | Addax & Oryx Foundation | N/A | N | Y | N | N | Y | N | Low success rate (1%); Root causes of poverty; Africa and Middle East; Non-profit/NGO-led; Local community involvement; Holistic (Health, education, community development, environment) | Rolling | https://addax-oryx-foundation.org/en/submit-a-project | ||||||||||||||||
8 | Humanitarian Grand Challenge | Transition to Scale | Y | N | N | N | Y | N | Humanitarian crises; Health supplies and equipment; WASH; Access to data; Energy | Rolling | 3,000,000 | CAD | https://www.grandchallenges.ca/funding-opportunities/ | ||||||||||||||
9 | Grand Challenges Canada | Transition to Scale | Y | Y | N | N | Y | N | Scaling innovations in Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options for safe pregnancy termination; Requires match-funding' SSA-led | Rolling | 3,000,000 | CAD | https://www.grandchallenges.ca/funding-opportunities/ | ||||||||||||||
10 | Roncalli International Foundation | Grant | N | Y | N | Y | Y | Y | Requires Canadian organization to receive funds, but partnership with implementing community | Rolling | 35,000 | CAD | 12 | https://roncalli.ca/en/grant-application/eligibility-criteria/ | |||||||||||||
11 | Nestle Foundation | Pilot Grants | Y | N | N | Y | Y | N | LMIC-based; Clinical research in nutrition; Public health relevance; Potetential for implementation; Nutrition education/health promotion | Rolling | 20,000 | USD | 24 | https://www.nestlefoundation.org/apply.html | |||||||||||||
12 | Nestle Foundation | Small Research Grants | Y | N | N | Y | Y | N | LMIC-based; Usually after Pilot Grant; Clinical research in nutrition; Public health relevance; Potetential for implementation; Nutrition education/health promotion | Rolling | 50,000 | USD | 24 | https://www.nestlefoundation.org/apply.html | |||||||||||||
13 | Nestle Foundation | Large Research Grants | Y | N | N | Y | Y | N | LMIC-based; Usually after Pilot Grant; Clinical research in nutrition; Public health relevance; Potetential for implementation; Nutrition education/health promotion | Rolling | 300,000 | USD | 36 | https://www.nestlefoundation.org/apply.html | |||||||||||||
14 | Nestle Foundation | Training Grant | Y | N | N | Y | Y | N | MSc or PhD Student; LMIC-based; Clinical research in nutrition; Public health relevance; Potetential for implementation; Nutrition education/health promotion | Rolling | 20,000 | USD | 24 | https://www.nestlefoundation.org/apply.html | |||||||||||||
15 | Nestle Foundation | Re-entry Grants | Y | N | N | N | Y | N | LMIC-based; Supports return to home country; Needs support from host institution | Rolling | 50,000 | USD | 36 | https://www.nestlefoundation.org/apply.html | |||||||||||||
16 | Commonweath Fund | Project Grants | Y | Y | N | N | Y | N | Primarily US-focused; Global priorities include: models of effective primary care, policy solutions to improve health care affordability , and partners with access to data sets to complete international comparisons of access, cost, and quality of care. Clinical, policy, or implementation research | Rolling | 180,000 | USD | 12 | https://www.commonwealthfund.org/grants | |||||||||||||
17 | Fonds d'Innovation pour le Developpement | Preperation Grant | Y | N | N | N | Y | N | Funds must go to LMICs; Apply as an organization, not individual; aims to pilot, test and evaluate the impact of projects using rigorous scientific methods; For preparing for pilot or preperation for scaling grant | Rolling | 50,000 | EUR | 6 | https://fundinnovation.dev/en/launch-project | |||||||||||||
18 | Fonds d'Innovation pour le Developpement | Pilot Grant | Y | N | N | N | Y | N | Funds must go to LMICs; Apply as an organization, not individual; Testing innovations in real-world environment | Rolling | 200,000 | EUR | 24 | https://fundinnovation.dev/en/launch-project | |||||||||||||
19 | Fonds d'Innovation pour le Developpement | Test and Preparation for Scaling Up | Y | N | N | N | Y | N | Funds must go to LMICs; Apply as an organization, not individual; ; Testing for impact on larger scale and evaluating cost-effectiveness | Rolling | 1,500,000 | EUR | 36 | https://fundinnovation.dev/en/launch-project | |||||||||||||
20 | Fonds d'Innovation pour le Developpement | Scaling Up | Y | N | Y | N | Y | N | Funds must go to LMICs; Apply as an organization, not individual; aims to pilot, test and evaluate the impact of projects using rigorous scientific methods; Implementation following rigorous evidence of impact and cost-effectiveness | Rolling | 4,000,000 | EUR | 36 | https://fundinnovation.dev/en/launch-project | |||||||||||||
21 | Fonds d'Innovation pour le Developpement | Transformatiom of Public Policies | N | N | Y | N | Y | N | Funds must go to LMICs; Apply as an organization, not individual; Institutionalizing innovations or building capacity of governements to design, test, and evalution innovations | Rolling | 500,000 | EUR | 24 | https://fundinnovation.dev/en/launch-project | |||||||||||||
22 | Founders Pledge | Global Health and Development Fund | N | Y | N | N | Y | N | Implementation, not research. Global health and development programs, especially programs that can, in expectation, save a life for under $4,000, avert a DALY for under $70, or double income for one person at a cost of less than $30. Note that this includes interventions that affect economic growth. We don’t necessarily require that grantees be able to point to an RCT in order to demonstrate cost-effectiveness | Rolling | 300,000 | USD | https://www.founderspledge.com/requests-for-funding | ||||||||||||||
23 | Open Philanthropy | Grants - Global Health and Wellbeing: Scientific Research | Y | N | N | N | Y | N | Current topics of interest include road-spectrum antiviral drugs, vaccine development, basic immunology, some aspects of cardiovascular disease, Alzheimer’s disease, predicting mouse-to-human translation, control of inflammation, epigenetics, novel scientific tools and methods, malaria, and research on how biomedical research may be improved. | Rolling | 50,000 - 2,600,000 | USD | https://www.openphilanthropy.org/focus/scientific-research/ | ||||||||||||||
24 | |||||||||||||||||||||||||||
25 | |||||||||||||||||||||||||||
26 | |||||||||||||||||||||||||||
27 | |||||||||||||||||||||||||||
28 | |||||||||||||||||||||||||||
29 | |||||||||||||||||||||||||||
30 | |||||||||||||||||||||||||||
31 | |||||||||||||||||||||||||||
32 | |||||||||||||||||||||||||||
33 | |||||||||||||||||||||||||||
34 | |||||||||||||||||||||||||||
35 | |||||||||||||||||||||||||||
36 | |||||||||||||||||||||||||||
37 | |||||||||||||||||||||||||||
38 | |||||||||||||||||||||||||||
39 | |||||||||||||||||||||||||||
40 | |||||||||||||||||||||||||||
41 | |||||||||||||||||||||||||||
42 | |||||||||||||||||||||||||||
43 | |||||||||||||||||||||||||||
44 | |||||||||||||||||||||||||||
45 | |||||||||||||||||||||||||||
46 | |||||||||||||||||||||||||||
47 | |||||||||||||||||||||||||||
48 | |||||||||||||||||||||||||||
49 | |||||||||||||||||||||||||||
50 | |||||||||||||||||||||||||||
51 | |||||||||||||||||||||||||||
52 | |||||||||||||||||||||||||||
53 | |||||||||||||||||||||||||||
54 | |||||||||||||||||||||||||||
55 | |||||||||||||||||||||||||||
56 | |||||||||||||||||||||||||||
57 | |||||||||||||||||||||||||||
58 | |||||||||||||||||||||||||||
59 | |||||||||||||||||||||||||||
60 | |||||||||||||||||||||||||||
61 | |||||||||||||||||||||||||||
62 | |||||||||||||||||||||||||||
63 | |||||||||||||||||||||||||||
64 | |||||||||||||||||||||||||||
65 | |||||||||||||||||||||||||||
66 | |||||||||||||||||||||||||||
67 | |||||||||||||||||||||||||||
68 | |||||||||||||||||||||||||||
69 | |||||||||||||||||||||||||||
70 | |||||||||||||||||||||||||||
71 | |||||||||||||||||||||||||||
72 | |||||||||||||||||||||||||||
73 | |||||||||||||||||||||||||||
74 | |||||||||||||||||||||||||||
75 | |||||||||||||||||||||||||||
76 | |||||||||||||||||||||||||||
77 | |||||||||||||||||||||||||||
78 | |||||||||||||||||||||||||||
79 | |||||||||||||||||||||||||||
80 | |||||||||||||||||||||||||||
81 | |||||||||||||||||||||||||||
82 | |||||||||||||||||||||||||||
83 | |||||||||||||||||||||||||||
84 | |||||||||||||||||||||||||||
85 | |||||||||||||||||||||||||||
86 | |||||||||||||||||||||||||||
87 | |||||||||||||||||||||||||||
88 | |||||||||||||||||||||||||||
89 | |||||||||||||||||||||||||||
90 | |||||||||||||||||||||||||||
91 | |||||||||||||||||||||||||||
92 | |||||||||||||||||||||||||||
93 | |||||||||||||||||||||||||||
94 | |||||||||||||||||||||||||||
95 | |||||||||||||||||||||||||||
96 | |||||||||||||||||||||||||||
97 | |||||||||||||||||||||||||||
98 | |||||||||||||||||||||||||||
99 | |||||||||||||||||||||||||||
100 |